Rainer Oberbauer

Rainer Oberbauer

Auto-generated profile, based on publicly available information

Rainer Oberbauer

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2017 in Transplant International
Verified
Journal Article
Closed access
PDF file
AGAndreas Gleiss
Andreas Gleiss
RORainer Oberbauer
Rainer Oberbauer
Georg HeinzeGeorg Heinze
Georg Heinze
Immortal time bias is a problem arising from methodologically wrong analyses of time‐dependent events in survival analyses. We illustrate the problem by analysis of a kidney transplantation study. Following patients from transplantation to death, groups defined by the occurrence or nonoccurrence of graft failure during follow‐up seemingly had equal overall mortality. Such naive analysis assumes that patients were assigned to the two groups at time of transplantation, which actually are a consequence of occurrence of a time‐dependent event later during follow‐up. We introduce landmark analysis as the method of choice to avoid immortal time bias. Landmark analysis splits the follow‐up time at a common, prespecified time point, the so‐called landmark. Groups are then defined by time‐dependent events having occurred before the landmark, and outcome events are only considered if occurring after the landmark. Landmark analysis can be easily implemented with common statistical software. In our kidney transplantation example, landmark analyses with landmarks set at 30 and 60 months clearly identified graft failure as a risk factor for overall mortality. We give further typical examples from transplantation research and discuss strengths and limitations of landmark analysis and other methods to address immortal time bias such as Cox regression with time‐dependent covariables.

21 December 2004 in Transplant International
Verified
Journal Article
Open access
PDF file
RORainer Oberbauer
Rainer Oberbauer
GSGiuseppe Segoloni
Giuseppe Segoloni
JCJosep M. Campistol
Josep M. Campistol
HKHenri Kreis
Henri Kreis
AMAlfredo Mota
Alfredo Mota
FGfor the Rapamune Maintenance Regimen Study Group
for the Rapamune Maintenance Regimen Study Group
We report the 48‐month results of a trial testing whether withdrawal of cyclosporine (CsA) from a sirolimus (SRL)‐CsA‐steroid (ST) regimen would impact renal allograft survival. Eligible patients receiving SRL‐CsA‐ST from transplantation were randomly assigned at 3 months to remain on triple therapy (SRL‐CsA‐ST, n = 215) or to have CsA withdrawn and SRL trough concentrations increased (SRL‐ST, n = 215). SRL‐ST therapy resulted in significantly better graft survival, either when including death with a functioning graft as an event (84.2% vs. 91.5%, P = 0.024) or when censoring it (90.6% vs. 96.1%, P = 0.026). Calculated glomerular filtration rate (43.8 vs. 58.3 ml/min, P < 0.001) and mean arterial blood pressure (101.3 vs. 97.1 mmHg, P = 0.047) were also improved with SRL‐ST. Differences in the incidences of biopsy‐proven acute rejection after randomization (6.5% vs. 10.2%, SRL‐CsA‐ST versus SRL‐ST, respectively) and mortality (7.9% vs. 4.7%) were not significant. SRL‐CsA‐ST‐treated patients had significantly higher incidences of adverse events generally associated with CsA, whereas those in the SRL‐ST group experienced greater frequencies of events commonly related to higher trough levels of SRL. In conclusion, early withdrawal of CsA from a SRL‐CsA‐ST regimen rapidly improves renal function and ultimately results in better graft survival.

1 May 2017 in The Lancet
Verified
Journal Article
Closed access
TWThomas Wekerle
Thomas Wekerle
DSDorry Segev
Dorry Segev
RLRobert Lechler
Robert Lechler
RORainer Oberbauer
Rainer Oberbauer

1 March 2019 in The Lancet
Verified
Journal Article
Closed access
RRRoman Reindl-Schwaighofer
Roman Reindl-Schwaighofer
AHAndreas Heinzel
Andreas Heinzel
AKAlexander Kainz
Alexander Kainz
JSJessica van Setten
Jessica van Setten
KJKira Jelencsics
Kira Jelencsics
RORainer Oberbauer
Rainer Oberbauer

1 August 2015 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
DDDaniela Dunkler
Daniela Dunkler
PGPeggy Gao
Peggy Gao
SLShun Fu Lee
Shun Fu Lee
Georg HeinzeGeorg Heinze
Georg Heinze
CCCatherine M. Clase
Catherine M. Clase
RORainer Oberbauer
Rainer Oberbauer
Background and objectives Quantitative data for prediction of incidence and progression of early CKD are scarce in individuals with type 2 diabetes. Therefore, two risk prediction models were developed for incidence and progression of CKD after 5.5 years and the relative effect of predictors were ascertained. Design, setting, participants, & measurements Baseline and prospective follow-up data of two randomized clinical trials, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Outcome Reduction with Initial Glargine Intervention (ORIGIN), were used as development and independent validation cohorts, respectively. Individuals aged ≥55 years with type 2 diabetes and normo- or microalbuminuria at baseline were included. Incidence or progression of CKD after 5.5 years was defined as new micro- or macroalbuminuria, doubling of creatinine, or ESRD. The competing risk of death was considered as an additional outcome state in the multinomial logistic models. Results Of the 6766 ONTARGET participants with diabetes, 1079 (15.9%) experienced incidence or progression of CKD, and 1032 (15.3%) died. The well calibrated, parsimonious laboratory prediction model incorporating only baseline albuminuria, eGFR, sex, and age exhibited an externally validated c-statistic of 0.68 and an R2 value of 10.6%. Albuminuria, modeled to depict the difference between baseline urinary albumin/creatinine ratio and the threshold for micro- or macroalbuminuria, was mostly responsible for the predictive performance. Inclusion of clinical predictors, such as glucose control, diabetes duration, number of prescribed antihypertensive drugs, previous vascular events, or vascular comorbidities, increased the externally validated c-statistic and R2 value only to 0.69 and 12.1%, respectively. Explained variation was largely driven by renal and not clinical predictors. Conclusions Albuminuria and eGFR were the most important factors to predict onset and progression of early CKD in individuals with type 2 diabetes. However, their predictive ability is modest. Inclusion of demographic, clinical, and other laboratory predictors barely improved predictive performance.

20 December 2021 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
RRRoman Reindl-Schwaighofer
Roman Reindl-Schwaighofer
AHAndreas Heinzel
Andreas Heinzel
MMManuel Mayrdorfer
Manuel Mayrdorfer
RJRhea Jabbour
Rhea Jabbour
THThomas M. Hofbauer
Thomas M. Hofbauer
RORainer Oberbauer
Rainer Oberbauer
Kidney transplant recipients (KTRs) are considered at high risk for severe COVID-19 disease, and therefore, were prioritized for early SARS-CoV-2 vaccination.1,2 Immune response to vaccination is reduced in immunosuppressed individuals, including KTRs.3 In the US and the European Union, 2 classes of SARS-CoV-2 vaccines are currently available: (1) mRNA (mRNA-1273 [Moderna] and BNT162b2 [PfizerBioNTech]) and (2) viral vector (ChAdOx1 [AstraZeneca] and Ad26COVS1 [Janssen]). Among these, Ad26COVS1 is the only vaccine that has been shown to induce a protective immune response after a single dose.4